This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Essential cookies enable basic functions and are necessary for the website to function properly.
Statistics cookies collect information anonymously. This information helps us to understand how our visitors use our website.
Marketing cookies are used by third parties or publishers to display personalized advertisements. They do this by tracking visitors across websites.

About Radiopharmaceutical Therapy & Diagnostics

A radiopharmaceutical is a drug that contains a radioactive isotope and is used for diagnosis or treatment. These compounds are designed to target specific organs, tissues, or cellular receptors, allowing for imaging or therapeutic applications.


In diagnostics, radiopharmaceuticals help visualize and assess the function of organs and tissues (e.g., PET and SPECT scans).


In therapy, in certain diseases they deliver radiation to treat conditions like cancer.

Targeted Radiopharmaceuticals contain a targeting molecule and a radioisotope, conjugated by a chelating agent. The targeting molecule binds to a tumor-specific receptor, according to the lock and key principle. In most cases the targeting molecule can be used for both diagnosis and therapy – only the radioisotope must be changed. This opens the way for the application of Theranostics in the field of Precision Oncology.

Diagnostic and Therapeutic Applications of Radioisotopes in Medicine

Diagnostic Applications

For diagnostic applications, radioisotopes with shorter half-lives are typically used, though in some cases, those with longer half-lives may be utilized. When combined with highly sensitive molecular imaging technologies like PET (Positron Emission Tomography) or SPECT (Single Photon Emission Computed Tomography), they enable the visualization of organs and lesions, supporting early disease detection.

Therapeutic Applications

For therapeutic applications, medical radioisotopes with longer half-lives are applied for treatment. To destroy the tumor, minimal cytotoxic doses of ionizing radiation must be delivered to the tumor site before decay.  A highly precise localization of the toxicity ensures that healthy tissue in the surroundings of the targeted tumor is minimally affected.

Key Facts

Solid tumors such as neuroendocrine tumors (NETs), osteosarcoma or ovarian cancer can be detected at an early stage by in vivo imaging  

In most cases the targeting molecule can be used in a theranostic approach for diagnostics as well as for therapy  

Highly precise diagnostic and therapeutic radiopharmaceuticals can deal with specific tumors in the most effective manner

Targeted Radionuclide Therapy as a treatment option where other therapies are limited or even fail

A highly precise localization of the tumor ensures that healthy tissue in the surroundings of the targeted tumor is minimally affected.